Compare PBI & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PBI | JANX |
|---|---|---|
| Founded | 1920 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | N/A | 2021 |
| Metric | PBI | JANX |
|---|---|---|
| Price | $10.70 | $14.16 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | $11.67 | ★ $60.27 |
| AVG Volume (30 Days) | 2.7M | ★ 3.3M |
| Earning Date | 02-10-2026 | 11-06-2025 |
| Dividend Yield | ★ 2.98% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.45 | N/A |
| Revenue | ★ $1,931,125,000.00 | $10,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $25.43 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.88 | $13.76 |
| 52 Week High | $13.11 | $61.59 |
| Indicator | PBI | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 64.93 | 28.18 |
| Support Level | $10.54 | $13.82 |
| Resistance Level | $10.76 | $14.49 |
| Average True Range (ATR) | 0.21 | 0.61 |
| MACD | 0.08 | 0.08 |
| Stochastic Oscillator | 93.36 | 9.76 |
Pitney Bowes Inc is a technology-driven company that provides SaaS shipping solutions, mailing innovation, and financial services to clients around the globe. The company's reportable segments are SendTech Solutions and Presort Services. SendTech Solutions includes the revenue and related expenses from physical and digital mailing and shipping technology solutions, financing, services, supplies and other applications to help simplify and save on the sending, tracking and receiving of letters, parcels and flats. Presort Services includes the revenue and related expenses from sortation services to qualify large volumes of First Class Mail, Marketing Mail and Marketing Mail Flats/Bound Printed Matter for postal worksharing discounts. It derives maximum revenue from SendTech Solutions.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.